Literature DB >> 16679314

A novel repressor domain is required for maximal growth inhibition by the IRF-1 tumor suppressor.

Mirjam Eckert1, Sarah E M Meek, Kathryn L Ball.   

Abstract

Interferon regulatory factor-1 (IRF-1) is a transcription factor and tumor suppressor that can regulate gene expression in a manner requiring either its sequence specific DNA binding activity or its ability to bind the p300 coactivator. We show that IRF-1-mediated growth inhibition is dependent on the integrity of a C-terminal transcriptional enhancer domain. An enhancer subdomain (amino acids 301-325) that differentially regulates IRF-1 activity has been identified and this region mediates the repression of Cdk2. The repressor domain encompasses an LXXLL coregulator signature motif and mutations or deletions within this region completely uncouple transcriptional activation from repression. The loss of growth suppressor activity when the Cdk2-repressor domain of IRF-1 is mutated implicates repression as a determinant of its maximal growth inhibitory potential. The data link IRF-1 regulatory domains to its growth inhibitory activity and provide information about how differential gene regulation may contribute to IRF-1 tumor suppressor activity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16679314     DOI: 10.1074/jbc.M512589200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Replacement of the C-terminal tetrapeptide (314 PAPV 317 to 314 SSSM 317) in interferon regulatory factor-2 alters its N-terminal DNA-binding activity.

Authors:  Krishna Prakash; Pramod C Rath
Journal:  J Biosci       Date:  2010-12       Impact factor: 1.826

2.  Intracellular activation of interferon regulatory factor-1 by nanobodies to the multifunctional (Mf1) domain.

Authors:  Angeli Möller; Emmanuelle Pion; Vikram Narayan; Kathryn L Ball
Journal:  J Biol Chem       Date:  2010-09-03       Impact factor: 5.157

3.  IRF-1 inhibits NF-κB activity, suppresses TRAF2 and cIAP1 and induces breast cancer cell specific growth inhibition.

Authors:  Michaele J Armstrong; Michael T Stang; Ye Liu; Jin Yan; Eva Pizzoferrato; John H Yim
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

4.  Cooperative regulation of the interferon regulatory factor-1 tumor suppressor protein by core components of the molecular chaperone machinery.

Authors:  Vikram Narayan; Mirjam Eckert; Alicja Zylicz; Maciej Zylicz; Kathryn L Ball
Journal:  J Biol Chem       Date:  2009-06-05       Impact factor: 5.157

5.  Interferon regulatory factor-1 together with reactive oxygen species promotes the acceleration of cell cycle progression by up-regulating the cyclin E and CDK2 genes during high glucose-induced proliferation of vascular smooth muscle cells.

Authors:  Xi Zhang; Long Liu; Chao Chen; Ya-Li Chi; Xiang-Qun Yang; Yan Xu; Xiao-Tong Li; Shi-Lei Guo; Shao-Hu Xiong; Man-Ru Shen; Yu Sun; Chuan-Sen Zhang; Kai-Meng Hu
Journal:  Cardiovasc Diabetol       Date:  2013-10-14       Impact factor: 9.951

6.  Indoxyl sulfate induces intestinal barrier injury through IRF1-DRP1 axis-mediated mitophagy impairment.

Authors:  Yinghui Huang; Jie Zhou; Shaobo Wang; Jiachuan Xiong; Yin Chen; Yong Liu; Tangli Xiao; Yi Li; Ting He; Yan Li; Xianjin Bi; Ke Yang; Wenhao Han; Yu Qiao; Yanli Yu; Jinghong Zhao
Journal:  Theranostics       Date:  2020-06-05       Impact factor: 11.556

7.  GSK3β-SCFFBXW7α mediated phosphorylation and ubiquitination of IRF1 are required for its transcription-dependent turnover.

Authors:  Alexander J Garvin; Ahmed H A Khalaf; Alessandro Rettino; Jerome Xicluna; Laura Butler; Joanna R Morris; David M Heery; Nicole M Clarke
Journal:  Nucleic Acids Res       Date:  2019-05-21       Impact factor: 16.971

8.  IRF1-mediated downregulation of PGC1α contributes to cardiorenal syndrome type 4.

Authors:  Yinghui Huang; Shaobo Wang; Jie Zhou; Yong Liu; Changhong Du; Ke Yang; Xianjin Bi; Mingying Liu; Wenhao Han; Kailong Wang; Jiachuan Xiong; Song Wang; Yue Wang; Ling Nie; Chi Liu; Daohai Zhang; Jun Gu; Chunyu Zeng; Jinghong Zhao
Journal:  Nat Commun       Date:  2020-09-16       Impact factor: 14.919

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.